PAREXEL has made several new appointments to enhance its oncology expertise. Amy McKee, M.D., former Deputy Director of the U.S. FDA Oncology Center of Excellence, has been appointed to the company’s Regulatory Consulting team. She will be focused on building the company’s new cross-functional Oncology initiative.
 
Also, Matthew Cooney, M.D., a Medical Oncologist most recently with University Hospitals in Cleveland, OH, has been appointed senior medical director and therapeutic area lead for Oncology within PAREXEL’s Global Medical Services team, which has also added more than 10 oncologists to its global team in the past year.
 
“As oncology trials increase and become more complex, it is imperative to PAREXEL that we bring together the perspectives of key stakeholders in drug development – including regulatory bodies and the patient perspective,” said Peyton Howell, chief commercial and strategy officer, PAREXEL. “Coming from world-renowned organizations, these experts will work across PAREXEL to implement an approach for our clients that takes diverse viewpoints into consideration, and ultimately drives the delivery of important new therapies to patients battling cancer.”
 
Dr. McKee will serve as vice president, Regulatory Consulting Services and brings 11 years’ experience in the FDA. During her time at the FDA she held several positions such as Deputy Center Director of the Oncology Center of Excellence, Supervisory Associate Director of the Office of Hematology and Oncology Products (OHOP) and Deputy Office Director of OHOP, among others. While at the FDA, Dr. McKee was the signatory authority for products within OHOP. She was responsible for four divisions performing the scientific review and evaluation of hematology and oncology therapeutic drugs and biologics subject to regulation by the Center for Drug Evaluation and Research (CDER).
 
Matthew M. Cooney, M.D., joined PAREXEL in January 2019 as a senior medical director, Global TA Lead Oncology/Hematology within Global Medical Services. Dr. Cooney is board-certified in Medical Oncology, Hematology, and Internal Medicine. Dr. Cooney practiced clinical hematology and oncology for over 15 years with and was the Interim Division Chief as well as the Program Leader for Genitourinary Oncology. Dr. Cooney has significant expertise in the areas of genitourinary malignancies including prostate, bladder, and kidney cancer and in the use of wearable technologies and patient-reported outcomes in oncology.